Goldman Sachs’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.1M | Buy |
1,276,260
+81,933
| +7% | +$3.03M | ﹤0.01% | 1730 |
|
|
2025
Q4 | $50.3M | Sell |
1,194,327
-145,836
| -11% | -$5.88M | 0.01% | 1505 |
|
|
2025
Q3 | $46M | Sell |
1,340,163
-208,311
| -13% | -$5.98M | 0.01% | 1482 |
|
|
2025
Q2 | $41.9M | Buy |
1,548,474
+499,826
| +48% | +$14.5M | 0.01% | 1473 |
|
|
2025
Q1 | $31.1M | Sell |
1,048,648
-167,824
| -14% | -$6.4M | 0.01% | 1621 |
|
|
2024
Q4 | $48.2M | Sell |
1,216,472
-97,022
| -7% | -$3.67M | 0.01% | 1332 |
|
|
2024
Q3 | $44.7M | Buy |
1,313,494
+222,294
| +20% | +$6.25M | 0.01% | 1340 |
|
|
2024
Q2 | $23.6M | Buy |
1,091,200
+114,111
| +12% | +$2.4M | ﹤0.01% | 1752 |
|
|
2024
Q1 | $21.7M | Sell |
977,089
-238,857
| -20% | -$5.83M | ﹤0.01% | 1773 |
|
|
2023
Q4 | $33.5M | Sell |
1,215,946
-90,216
| -7% | -$2.18M | 0.01% | 1464 |
|
|
2023
Q3 | $29.2M | Buy |
1,306,162
+37,551
| +3% | +$966K | 0.01% | 1473 |
|
|
2023
Q2 | $32.3M | Sell |
1,268,611
-146,152
| -10% | -$3.54M | 0.01% | 1436 |
|
|
2023
Q1 | $31.5M | Buy |
1,414,763
+196,974
| +16% | +$4.76M | 0.01% | 1403 |
|
|
2022
Q4 | $28.9M | Sell |
1,217,789
-110,740
| -8% | -$2.57M | 0.01% | 1626 |
|
|
2022
Q3 | $22.1M | Buy |
1,328,529
+278,684
| +27% | +$6.27M | 0.01% | 1775 |
|
|
2022
Q2 | $20.9M | Buy |
1,049,845
+575,949
| +122% | +$11.6M | 0.01% | 1857 |
|
|
2022
Q1 | $13.1M | Buy |
473,896
+58,195
| +14% | +$1.66M | ﹤0.01% | 2424 |
|
|
2021
Q4 | $17.1M | Buy |
415,701
+17,286
| +4% | +$764K | ﹤0.01% | 2270 |
|
|
2021
Q3 | $18.5M | Sell |
398,415
-383,859
| -49% | -$16.8M | ﹤0.01% | 2136 |
|
|
2021
Q2 | $31.3M | Sell |
782,274
-175,203
| -18% | -$7.49M | 0.01% | 1666 |
|
|
2021
Q1 | $51.5M | Buy |
957,477
+428,450
| +81% | +$24.7M | 0.01% | 1150 |
|
|
2020
Q4 | $25.9M | Buy |
529,027
+187,010
| +55% | +$8.67M | 0.01% | 1639 |
|
|
2020
Q3 | $11.1M | Buy |
342,017
+51,489
| +18% | +$1.64M | ﹤0.01% | 2225 |
|
|
2020
Q2 | $7.52M | Sell |
290,528
-499,772
| -63% | -$12.5M | ﹤0.01% | 2471 |
|
|
2020
Q1 | $19.2M | Buy |
790,300
+83,208
| +12% | +$2.09M | 0.01% | 1537 |
|
|
2019
Q4 | $19.7M | Sell |
707,092
-61,518
| -8% | -$1.59M | 0.01% | 1880 |
|
|
2019
Q3 | $18.4M | Buy |
768,610
+44,231
| +6% | +$1.18M | 0.01% | 1847 |
|
|
2019
Q2 | $20.7M | Sell |
724,379
-201,920
| -22% | -$5.04M | 0.01% | 1831 |
|
|
2019
Q1 | $23.2M | Buy |
926,299
+194,232
| +27% | +$3.71M | 0.01% | 1743 |
|
|
2018
Q4 | $9.21M | Sell |
732,067
-15,846
| -2% | -$187K | ﹤0.01% | 2402 |
|
|
2018
Q3 | $7.14M | Buy |
747,913
+674,061
| +913% | +$7.43M | ﹤0.01% | 2717 |
|
|
2018
Q2 | $690K | Buy |
73,852
+33,794
| +84% | +$238K | ﹤0.01% | 4312 |
|
|
2018
Q1 | $223K | Sell |
40,058
-10,114
| -20% | -$62.6K | ﹤0.01% | 4944 |
|
|
2017
Q4 | $328K | Buy |
50,172
+21,088
| +73% | +$157K | ﹤0.01% | 5128 |
|
|
2017
Q3 | $255K | Sell |
29,084
-14,483
| -33% | -$118K | ﹤0.01% | 5592 |
|
|
2017
Q2 | $363K | Buy |
43,567
+29,997
| +221% | +$245K | ﹤0.01% | 5350 |
|
|
2017
Q1 | $125K | Sell |
13,570
-2,969
| -18% | -$24.3K | ﹤0.01% | 5966 |
|
|
2016
Q4 | $128K | Buy |
+16,539
| New | +$124K | ﹤0.01% | 6021 |
|
|
2016
Q3 | – | Sell |
-10,970
| Closed | -$55K | – | 7200 |
|
|
2016
Q2 | $55K | Buy |
+10,970
| New | +$58.8K | ﹤0.01% | 6396 |
|
|
2016
Q1 | – | Sell |
-63,084
| Closed | -$454K | – | 7344 |
|
|
2015
Q4 | $454K | Buy |
63,084
+14,491
| +30% | +$97.6K | ﹤0.01% | 5007 |
|
|
2015
Q3 | $228K | Buy |
48,593
+9,565
| +25% | +$91.1K | ﹤0.01% | 5887 |
|
|
2015
Q2 | $435K | Buy |
39,028
+14,648
| +60% | +$144K | ﹤0.01% | 5334 |
|
|
2015
Q1 | $177K | Buy |
+24,380
| New | +$200K | ﹤0.01% | 6105 |
|
|
2014
Q3 | – | Sell |
-10,308
| Closed | -$176K | – | 7270 |
|
|
2014
Q2 | $176K | Buy |
+10,308
| New | +$148K | ﹤0.01% | 6295 |
|
Other funds holding VCYT
VPM
VCM
AIM
Goldman Sachs's VCYT Position: Q1 2026 in Review
Goldman Sachs increased its Veracyte (VCYT) stake by 6.9% in Q1 2026, buying an estimated $3.03M and bringing the position to 1,276,260 shares worth $41.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1730.
Goldman Sachs first reported a position in VCYT in Q2 2014 and has held it in 44 quarters since. The position peaked at $51.5M in Q1 2021. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.
- Goldman Sachs held 1,276,260 shares of Veracyte worth $41.1M as of Q1 2026.
- Goldman Sachs bought 81,933 Veracyte shares in Q1 2026, an estimated $3.03M.
- Veracyte made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1730 holding.
- Goldman Sachs first reported a position in Veracyte in Q2 2014 and has held it in 44 quarters since.
- Goldman Sachs's Veracyte position peaked at $51.5M in Q1 2021.
- 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.